The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

Michelle J. Pena, Dick de Zeeuw, Dennis Andress, John J. Brennan, Ricardo Correa-Rotter, Blai Coll, Donald E. Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W. Tobe, Robert Toto, Hans Henrik Parving, Shoba Sharma, Tom Corringham, Kumar Sharma, Hiddo J.L. Heerspink

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR < 60 mL/min/1.73 m2. After 12 weeks of atrasentan treatment in patients with eGFR < 60 mL/min/1.73 m2, a single-value index of the metabolites changed by −0.31 (95%CI −0.60 to −0.02; P =.035), −0.08 (−12 to 0.29; P =.43) and 0.01 (−0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25 mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (−0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25 mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR < 60 mL/min/1.73 m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

Original languageEnglish
Pages (from-to)749-753
Number of pages5
JournalDiabetes, Obesity and Metabolism
Volume19
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Type 2 Diabetes Mellitus
Placebos
Albuminuria
Diabetic Nephropathies
atrasentan
Gas Chromatography-Mass Spectrometry
Therapeutics
Urine
Population

Keywords

  • diabetic kidney disease
  • eGFR decline
  • metabolomics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Pena, M. J., de Zeeuw, D., Andress, D., Brennan, J. J., Correa-Rotter, R., Coll, B., ... Heerspink, H. J. L. (2017). The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 19(5), 749-753. https://doi.org/10.1111/dom.12864

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. / Pena, Michelle J.; de Zeeuw, Dick; Andress, Dennis; Brennan, John J.; Correa-Rotter, Ricardo; Coll, Blai; Kohan, Donald E.; Makino, Hirofumi; Perkovic, Vlado; Remuzzi, Giuseppe; Tobe, Sheldon W.; Toto, Robert; Parving, Hans Henrik; Sharma, Shoba; Corringham, Tom; Sharma, Kumar; Heerspink, Hiddo J.L.

In: Diabetes, Obesity and Metabolism, Vol. 19, No. 5, 01.05.2017, p. 749-753.

Research output: Contribution to journalArticle

Pena, MJ, de Zeeuw, D, Andress, D, Brennan, JJ, Correa-Rotter, R, Coll, B, Kohan, DE, Makino, H, Perkovic, V, Remuzzi, G, Tobe, SW, Toto, R, Parving, HH, Sharma, S, Corringham, T, Sharma, K & Heerspink, HJL 2017, 'The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy', Diabetes, Obesity and Metabolism, vol. 19, no. 5, pp. 749-753. https://doi.org/10.1111/dom.12864
Pena, Michelle J. ; de Zeeuw, Dick ; Andress, Dennis ; Brennan, John J. ; Correa-Rotter, Ricardo ; Coll, Blai ; Kohan, Donald E. ; Makino, Hirofumi ; Perkovic, Vlado ; Remuzzi, Giuseppe ; Tobe, Sheldon W. ; Toto, Robert ; Parving, Hans Henrik ; Sharma, Shoba ; Corringham, Tom ; Sharma, Kumar ; Heerspink, Hiddo J.L. / The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. In: Diabetes, Obesity and Metabolism. 2017 ; Vol. 19, No. 5. pp. 749-753.
@article{a05dacd31671427da3b86f9ac9b9e216,
title = "The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy",
abstract = "We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR < 60 mL/min/1.73 m2. After 12 weeks of atrasentan treatment in patients with eGFR < 60 mL/min/1.73 m2, a single-value index of the metabolites changed by −0.31 (95{\%}CI −0.60 to −0.02; P =.035), −0.08 (−12 to 0.29; P =.43) and 0.01 (−0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25 mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (−0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25 mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR < 60 mL/min/1.73 m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.",
keywords = "diabetic kidney disease, eGFR decline, metabolomics",
author = "Pena, {Michelle J.} and {de Zeeuw}, Dick and Dennis Andress and Brennan, {John J.} and Ricardo Correa-Rotter and Blai Coll and Kohan, {Donald E.} and Hirofumi Makino and Vlado Perkovic and Giuseppe Remuzzi and Tobe, {Sheldon W.} and Robert Toto and Parving, {Hans Henrik} and Shoba Sharma and Tom Corringham and Kumar Sharma and Heerspink, {Hiddo J.L.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/dom.12864",
language = "English",
volume = "19",
pages = "749--753",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

AU - Pena, Michelle J.

AU - de Zeeuw, Dick

AU - Andress, Dennis

AU - Brennan, John J.

AU - Correa-Rotter, Ricardo

AU - Coll, Blai

AU - Kohan, Donald E.

AU - Makino, Hirofumi

AU - Perkovic, Vlado

AU - Remuzzi, Giuseppe

AU - Tobe, Sheldon W.

AU - Toto, Robert

AU - Parving, Hans Henrik

AU - Sharma, Shoba

AU - Corringham, Tom

AU - Sharma, Kumar

AU - Heerspink, Hiddo J.L.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR < 60 mL/min/1.73 m2. After 12 weeks of atrasentan treatment in patients with eGFR < 60 mL/min/1.73 m2, a single-value index of the metabolites changed by −0.31 (95%CI −0.60 to −0.02; P =.035), −0.08 (−12 to 0.29; P =.43) and 0.01 (−0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25 mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (−0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25 mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR < 60 mL/min/1.73 m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

AB - We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected during the RADAR study which was a randomized, double-blind, placebo-controlled trial that tested the effects of atrasentan on albuminuria reduction in patients with type 2 diabetes and nephropathy. At baseline, 4 of the 13 metabolites, quantified by gas-chromatography mass spectrometry, were below detectable levels, and 6 were reduced in patients with eGFR < 60 mL/min/1.73 m2. After 12 weeks of atrasentan treatment in patients with eGFR < 60 mL/min/1.73 m2, a single-value index of the metabolites changed by −0.31 (95%CI −0.60 to −0.02; P =.035), −0.08 (−12 to 0.29; P =.43) and 0.01 (−0.21 to 0.19; P =.913) in placebo, atrasentan 0.75 and 1.25 mg/d, respectively. The metabolite index difference compared to placebo was 0.13 (−0.17 to 0.43; P =.40) and 0.35 (0.05-0.65; P =.02) for atrasentan 0.75 and 1.25 mg/d, respectively. These data corroborate previous findings of mitochondrial dysfunction in patients with type 2 diabetes, nephropathy and eGFR < 60 mL/min/1.73 m2, suggesting that atrasentan may prevent the progression of mitochondrial dysfunction common to this specific patient population. Future studies of longer treatment duration with atrasentan are indicated.

KW - diabetic kidney disease

KW - eGFR decline

KW - metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85013371547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013371547&partnerID=8YFLogxK

U2 - 10.1111/dom.12864

DO - 10.1111/dom.12864

M3 - Article

VL - 19

SP - 749

EP - 753

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 5

ER -